Physician profile
Mary E Littlefield
NPI 1619955119
$703.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $14.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $121.34 | 2021-2022 | |
| Amgen INC. | $89.27 | 2021 | |
| Abbvie INC. | $69.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.85 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.60 | 2021 | |
| Kyowa Kirin, INC. | $53.25 | 2021 | |
| Amarin Pharma, INC. | $45.62 | 2021 | |
| Pfizer INC. | $33.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.21 | 2021 | |
| Eisai INC. | $21.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2021 | |
| Astellas Pharma US INC | $16.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Littlefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.